If you want more than just a prescription, Nooms built-in support system makes it a standout choice
Orforglipron (LY3502970) is a non-peptide GLP-1R agonist currently in clinical development that has demonstrated promising effects on glycemic control and body weight reduction, highlighting the continued expansion of GLP-1-based therapeutic strategies [4]
Thursday at 11pm the next
Your healthcare team can provide personalised advice on managing Mounjaro alongside other medications and optimising your overall cardiovascular and metabolic health
The direct receptor effect, combined with any weight loss that occurs, creates a dual benefit that addresses IIH from two directions simultaneously
For weight management, research indicates that tirzepatide produces superior weight loss compared to semaglutide, with patients losing 20.2% of body weight versus 13.7%, respectively